Tim Brown, PharmD, BCACP, FASHP Director of Clinical Pharmacotherapy, Akron General Medical Center for Family Medicine Professor, Northeast Ohio
|
|
- Lillian Tucker
- 5 years ago
- Views:
Transcription
1 Tim Brown, PharmD, BCACP, FASHP Director of Clinical Pharmacotherapy, Akron General Medical Center for Family Medicine Professor, Northeast Ohio Medical University
2 Objectives Review and discuss current changes in anticoagulation guidelines in relation to NOACs. Discuss stratification of risk using the CHADS2 and CHA2DS2Vasc scoring system for atrial fibrillation patients Review and discuss NOACs with regard to mechanism of action, drug interactions, side effects, and indication as compared to warfarin Identify the appropriate protocol to transition to and from NOACs in relation to warfarin, LMWHs, unfractionated heparin, and surgical procedures.
3 Executive Summary: Antithrombotic Therapy and Prevention of Thrombosis, 9 th Edition published in 2012 CHEST supplement.
4 CHEST Guideline Review Updated recommendations in All NOACs were not addressed Guidelines were updated based perception of the future therapies Warfarin remained the gold standard LMWH took center stage Bridging therapy VTE prevention pre/post CA treatment
5 True or False
6 True or False 20s In patients with acute DVT of the leg treated with LMWH, we suggest once- over twice-daily administration (Grade 2C). True
7 True or False 24s In patients with a first VTE that is an unprovoked PE and who have a low or moderate bleeding risk, we suggest extended anticoagulant therapy over 3 months of therapy. True
8 True or False 10s 9.1 a For patients taking VKAs with INRs between 4.5 and 10 and with no evidence of bleeding, we suggest against the routine use of vitamin K True
9 True of False 9s 3.1 For patients taking VKA therapy with consistently stable INRs, we suggest an INR testing frequency of up to 8 weeks rather than every 4 weeks False the suggestion is 12 weeks
10 True of False 9s 3.2 For patients taking VKAs with previously stable therapeutic INRs who present with a single out-of-range INR of 0.5 below or above therapeutic, we suggest continuing the current dose and testing the INR within 1 to 2 weeks True
11 True or False 14s 2.1 In patients who require temporary interruption of a VKA before surgery, we recommend stopping VKAs approximately 3 days before surgery. False- 5 days is recommended
12 True or False 15s (sic)in patients who require a minor dental procedure, a minor dermatologic procedure, and/or cataract surgery, we suggest to continue VKAs instead of other therapies. True
13 True or False 15s 2.4 In patients with a mechanical heart valve, atrial fibrillation, or VTE at high risk for thromboembolism, we suggest no bridging anticoagulation during interruption of VKA therapy False-Always bridge VKA therapy
14 True or False 15s 3.6 In patients who are receiving ASA and require CABG, we suggest continuing ASA around the time of surgery instead of stopping ASA 7 to 10 days before surgery (Grade 2C), as well as those on dual therapy should continue ASA but clopidogrel/ prasugrel should be stopped 5 days before surgery True
15 AHA/ACC/HRS Guideline for Management of Patients with Atrial Fibrillation, Executive Summary published in JACC in 2014.
16 Who Receives Anticoagulation? Individualized based on: CVA risk Bleeding risk Patient's preference All types of A Fib are treated the same with stratification of risk for thromboembolism Some patients in borderline risk categories may prefer no anticoagulation Some patients may be at a high risk for bleeds and not be candidates for therapy
17 Who Receives Anticoagulation? CHADS2 Validated - 2% increase in CVA rate for each 1 point increase However a score of 1 is considered intermediate risk Lowest risk may not be well identified Score of 2 from CVA/TIA is not equal risk as the score from other risk factors CHA2DS2-VASc is PREFERRED Broader score (0 to 9) Women cannot achieve a score of 0 Better discrimination of stroke risk More predictably with the lower risk category
18 Who Receives Anticoagulation?
19 Who Receives Anticoagulation? Considered for: CHA2DS2-VASc score of 1 Duration of <48h and low risk Recommended for: Nonvalvular A Fib Prior CVA or TIA CHA2DS2-VASc score of 2 or greater Hypertrophic cardiomyopathy Mechanical heart valves Cardioversion candidates
20 Who Receives Anticoagulation? Bleeding Risk Assessment: RIETE and HEMORR2HAGES HAS-BLED Score of 3 potential high risk HTN (SBP>160) Abnormal Liver or Renal Function History of Stroke or Bleeding Labile INRs Elderly (>65yo) Use Drugs that Promote Bleeding or ETOH abuse
21 Review of Warfarin Therapy
22 Warfarin Gold standard for comparison Numerous clinical trials showing efficacy and adverse outcomes DOC in valvular issues including AF Remains the inexpensive option Numerous drug and food interactions Only one where compliance can be assessed Narrow therapeutic window (INR 2-3) Does not begin to work immediately Half life of Vitamin K factors are reason II, VII, IX, X
23 Warfarin
24 Warfarin Cursory review of literature 64% RR reduction for ischemic and hemorrhage CVAs ARR 2.7%/yr Cochrane Collaboration review ARR 2.6%/yr or about 25 CVAs prevented annually per 1000 subjects treated BAFTA Head to Head with ASA in older pts Warfarin was superior to ASA No significant increase in bleeding
25 Warfarin
26 Warfarin Maintenance Dosing Suggested MD Adjustment Takes 5 days to see dosing adjustment effect on INR Adjust WEEKLY dose by 5-25% Check INR every 1-2 weeks until stable Can extend INR check interval as comfortable Maximum is 3 mos per Chest Home INR monitoring exists
27 Warfarin Bridging Therapy Certain procedures do not require interruption Dental extraction(s) Cataract surgery Colonoscopy Pacer, ICDs, ablations, angiography Risk stratification when interruption required Based on CHA2DS2-Vasc Score 2 Timing of VTE within last 3-12 months Valve replacement with prosthesis and type TIA and/or CVA within last 6 mos
28 Bridging Therapy in A. Fib. Low Risk: CHADS2 score 0-2 with no previous CVA and/or TIA No bridge or consider low dose LMWH Moderate Risk: CHADS2 score of 3-4 Bridge with full dose LMWH High Risk: CHADS2 score of 5-6 Bridge with full dose LMWH Chest 2008;133:S
29 Warfarin-Bridging Therapy If INR is 2-3 Start holding warfarin 5 days prior to procedure Initiate LMWH 3 days prior to procedure (INR should be < 2.5) Last dose of LMWH 24 h prior to procedure Resume BOTH Warfarin and LMWH h post BUT If high risk for bleed resume LMWH h post INR and CBC Day 3, then on Day 5 start daily INRs until therapeutic If INR >4 Same as above but if INR >1.5 on Day 2 consider oral vitamin K 2.5mg
30 Dabigatran Rivaroxaban Apixaban
31 Dabigatran (Pradaxa): Mechanism of Action Univalent, competitive, reversible direct thrombin inhibitor Binds to active site inactivates fibrin-bound & unbound thrombin Thrombin Inhibition Prevents Fibrinogen fibrin conversion Positive feedback amplification Platelet activation Fibrinolysis Circulation 2005; 112: Thromb Haemost 2010; 103: Thromb Haemost. 2011; 105:371-8.
32 Dabigatran: Mechanism of Action Ann Pharmacother 2011; 45:990-9.
33 Circulation 2005; 112: Thromb Haemost 2010; 103: Thromb Haemost. 2011; 105: Dabigatran: Pharmacokinetics Dabigatran etexilate (prodrug) + esterases dabigatran (active) Rapidly absorbed & hydrolyzed = peak plasma levels within 1.5 hrs NOT metabolism by the cytochrome P450 enzymes Dabigatran etexilate = p-glycoprotein substrate Plasma protein binding: ~35% Few displacement interactions & dialyzable Predominant elimination pathway: RENAL (80%) Creatinine clearance most important factor for drug exposure Terminal half-life: hrs
34 Dabigatran: Dosing Nonvalvular afib (NVAF) 150mg BID Prevents 5 more CVAs per 1000 pts/yr than warfarin (RELY Trial) Postoperative thromboprophylaxis Knee and Hip 110mg post op then 220mg/d x d up to 35 d Treatment of DVT and PE Treat with a parenteral anticoagulant for 5-10 days then 150mg BID Reduce the risk of recurrence of DVT and PE 150 mg BID Caution >75yo Poor renal function Underweight H/O GI bleed
35 Dabigatran: Conversion Manufacturer Recommendations Warfarin to dabigatran Stop warfarin and start dabigatran when INR < 2 Dabigatran to warfarin LMWH/Fondaparinux to dabigatran IV heparin to dabigatran Dabigatran to parenteral anticoagulant DC dabigatran 3 d after starting warfarin. CLcr ml/min: DC dabigatran 2 d after starting warfarin. CL ml/min: DC dabigatran 1 d after starting warfarin. DC parenteral anticoagulant and give dabigatran 0-2 h before next parenteral dose would have been given Administer 1 st dose of dabigatran at time of discontinuation of IV infusion CLcr > 30 ml/min: Start parenteral anticoagulant 12 h after the last dose of dabigatran CLcr < 30 ml/min: Start parenteral anticoagulant 24 h after the last dose of dabigatran
36 Dabigatran: Perioperative Management Calculated creatinine clearance ml/min Standard risk of bleeding High risk of bleeding >50 1 day 2 days days 4 days 30 4 days 6 days Blood 2012;119:
37 Dabigatran Drug Interactions Increased Effect G-glycoprotein Inhibitors Amiodarone Dronedarone Verapamil Clarithromycin Ketoconazole Antiplatelet Salicylates Plavix Effient Brillinta Decreased Effect Decrease Gastric ph Antacids PPIs H2 Antagonists Hepatic Inducers Rifampin Carbamazepine St. John s Wort Pradaxa package insert. FDA.
38 m a Rivaroxaban (Xarelto): Mechanism of Action
39 Rivaroxaban: Pharmacokinetics Rivaroxaban is rapidly absorbed after administration Peak plasma levels within 2-4 hrs Maximal Factor Xa inhibition = 1-4 hours Metabolized by hepatic oxidation CYP3A4/5 & CYP2J2 Avoid concomitant use with strong CYP3A4 inhibitors/inducers Plasma protein binding: ~93% NOT dialyzable Bioavailability % Terminal half-life: 5-13 hrs Eliminated via renal (66%) AND fecal/biliary (33%) route Renal dose adjustment required for CrCl <50 ml/min
40 Rivaroxaban: Indications Dosing Should be taken with food, preferably dinner Indication Atrial fibrillation DVT/PE VTE prophylaxis Dose 20 mg daily 15 mg daily (CrCl ml/min) 15 mg BID x 21 days, then 20 mg daily 10 mg daily Proved to be noninferior to warfarin in CVA prevention and VTE management (Rocket AF and EINSTEIN-DVT trials) Avoid Use CrCl< 15 ml/min Significant hepatic disease (Child-Pugh B or C)
41 Rivaroxaban: Drug interactions Increased Effect Azoles Fluconzaole, Itraconazole, Voriconazole Macrolides Clarithromycin Calcium Channel Blockers Verapamil Protease inhibitors Ritonavir Decreased Effect Hepatic Inducers St. John s Wort Carbamazepine, Phenytoin Xarelto package insert. FDA.
42 Rivaroxaban: Conversion From Warfarin Initiate Rivaroxaban when INR <3 To Warfarin Initiate warfarin and LMWH 24 h after last dose of Rivaroxaban From LMWH Initiate 2h prior to the next regularly scheduled dose of LMWH To LMWH Initiate 24h after the last dose of Rivaroxaban
43 Rivaroxaban: Perioperative Management Calculated creatinine clearance ml/min Standard risk of bleeding High risk of bleeding >50 1 day 3 days < 50 2 days 5 days Blood 2012;119:
44 m a Apixaban (Eliquis): Mechanism of Action
45 Apixaban: Pharmacokinetics Apixaban is rapidly absorbed after administration Peak plasma levels within 3-4 hrs Take with or without food and can crush Metabolized by hepatic oxidation CYP3A4/5 & CYP2J2 Avoid concomitant use with strong CYP3A4 inhibitors/inducers Plasma protein binding: ~87% NOT dialyzable Bioavailability 50% Terminal half-life: 12 hrs Eliminated via renal (27%) AND fecal/biliary (73%) route Renal dose adjustment if SCr 1.5mg/dl
46 . Apixaban: Indications NVAF 5 mg BID 2.5 mg BID if 2 or more of the following met: Age > 80 years old Weight < 60 kg Scr > 1.5 mg/dl Treatment and prevention of VTE Initial 10mg BID x 7 d then 5mg BID x 3-6 mos Extended timeline reduce to 2.5mg BID Hip and Knee post op 2.5mg BID 12 days post knee but 35 days post hip Renal dosing Mild-to-moderate: No dosage adjustment required SCr 1.5 mg/dl: 2.5 mg BID if patient has 1 additional characteristic of age 80 years or weight 60 kg ESRD on HD: 5 mg BID; decrease dose to 2.5 mg BID if 1 additional characteristic of age 80 years or weight 60 kg is present
47 Apixaban: Indications AMPLIFY and AMPLIFY-EXT Approval 8/21/14 Non-inferior to traditional management Superior with adverse effects like major bleeding ARISTOTLE results 3 more CVAs prevented, ten major bleed avoided, and 4 deaths prevented for every 1000 pts/yr compared to warfarin Demonstrated superiority against Warfarin Seeing an increase in use due to the study results Less bleeding noted vs. Dabigatran
48 Apixaban: Drug Interactions Increased Effect Azole antifungals Fluconazole, ketoconazole Calcium channel blockers Verapamil Anti Seizure Antiplatelet NSAIDs ASA Decreased Effect Beta Blocker Atenolol Hepatic Inducers Rifampin Cambamazepine Phenytoin St Johns Wort Eliquis package insert. FDA.
49 Apixaban: Conversion From Warfarin Initiate when INR <2 To Warfarin Initiate LMWH and warfarin when next dose of Apixaban is scheduled From LMWH Start Apixaban at the next regularly scheduled LMWH dose To LMWH Start LMWH at the next regularly scheduled Apixaban dose
50 Apixaban: Perioperative Management Calculated creatinine clearance ml/min Standard risk of bleeding High risk of bleeding Not a factor unless SCr 1.5mg/dl 1 day 2 days
51 Pharmacokinetic Comparison Dabigatran Rivaroxaban Apixaban MOA Diract Thrombin (IIA) inhibitor Direct Xa inhibitor Direct Xa inhibitor Bioavailability 6-7% 80% 50% T max 1.5h 2-4h 2-3h T 1/ h 9-13h 8-15h Hepatic metabolism Prodrug, glucuronidation CYP enzymes CYP enzymes Drug Interactions P-gp CYP3A4, Pg-p CYP3A4, P-gp Protein binding 35% 90% 87% Dialyzable Yes No No Renal elimination 80% 66% 27% 5 1
52 Reversal of NOACs Am J Hematol 2012:87:S141-S145.
53 A. Spinal injections B. Open cholecystectomy C. Colonoscopy D. Root Canal E. None of the above
54 A. Dabigatran B. Rivaroxaban C. Apixaban D. All the above
55 A. True B. False
56 Questions? Go with the flow and don t be a drip!!
Oral Anticoagulants Update. Elizabeth Renner, PharmD, BCPS, BCACP, CACP Outpatient Cardiology and Anticoagulation
Oral Anticoagulants Update Elizabeth Renner, PharmD, BCPS, BCACP, CACP Outpatient Cardiology and Anticoagulation Objectives List the direct oral anticoagulant (DOAC) drugs currently available Describe
More informationWhat s new with DOACs? Defining place in therapy for edoxaban &
What s new with DOACs? Defining place in therapy for edoxaban & Use of DOACs in cardioversion Caitlin M. Gibson, PharmD, BCPS Assistant Professor, Department of Pharmacotherapy University of North Texas
More informationEdoxaban. Direct Xa inhibitor Direct thrombin inhibitor Direct Xa inhibitor Direct Xa inhibitor
This table provides a summary of the pharmacotherapeutic properties, side effects, drug interactions and other important information on the four anticoagulant medications currently in use or under review
More informationNew Anticoagulants Therapies
New Anticoagulants Therapies Rachel P. Rosovsky, MD, MPH October 22, 2015 Conflicts of Interest No disclosures 2 Agenda 3 Historical perspective Novel oral anticoagulants Stats Trials Approval Concerns/Limitations
More informationSurvey patients for Sx, signs of AF. Establish AF Dx. Evaluate & Tx underlying heart disease/other causes. Assess adequacy of rate or rhythm control
Suggested General Approach to Managing Atrial Fibrillation Survey patients for Sx, signs of AF Establish AF Dx ECG Holter Event monitor Implanted device (pacer) Determine & Tx stroke risk (CHA 2 DS 2 VASc)
More informationNEW/NOVEL ORAL ANTICOAGULANTS (NOACS): COMPARISON AND FREQUENTLY ASKED QUESTIONS
NEW/NOVEL ORAL ANTICOAGULANTS (NOACS): COMPARISON AND FREQUENTLY ASKED QUESTIONS OBJECTIVES: To provide a comparison of the new/novel oral anticoagulants (NOACs) currently available in Canada. To address
More informationJoshua D. Lenchus, DO, RPh, FACP, SFHM Associate Professor of Medicine and Anesthesiology University of Miami Miller School of Medicine
Joshua D. Lenchus, DO, RPh, FACP, SFHM Associate Professor of Medicine and Anesthesiology University of Miami Miller School of Medicine Antithrombotics Antiplatelets Aspirin Ticlopidine Prasugrel Dipyridamole
More informationUpdate on Oral Anticoagulants. Dr. Miten R. Patel Cancer Specialists of North Florida Cell
Update on Oral Anticoagulants Dr. Miten R. Patel Cancer Specialists of North Florida Cell 904-451-9820 Email miten.patel@csnf.us Overview Highlights of the 4 new approved oral anticoagulants Results from
More informationNibal R. Chamoun, Pharm.D., BCPS Clinical Assistant Professor of Pharmacy Practice at the Lebanese American University Clinical Pharmacy Coordinator
Nibal R. Chamoun, Pharm.D., BCPS Clinical Assistant Professor of Pharmacy Practice at the Lebanese American University Clinical Pharmacy Coordinator at LAUMCRH Review the mechanism of action, indications
More informationNew Antithrombotic Agents DISCLOSURE
New Antithrombotic Agents DISCLOSURE Relevant Financial Relationship(s) Speaker Bureau None Research Alexion (PNH) delought@ohsu.edu Tom DeLoughery, MD FACP FAWM Oregon Health and Sciences University What
More informationThe DOACs. Update on Anticoagulation 10/20/2017. Dabigatran (Pradaxa ) Rivaroxaban (Xarelto ) Apixaban (Eliquis ) Edoxaban (Savaysa ) Objectives
Objectives Update on Anticoagulation JEFF REIST PHARMD, BCPS CLINICAL ASSOCIATE PROFESSOR UNIVERSITY OF IOWA COLLEGE OF PHARMACY At the conclusion of this program, the participant should be able to: List
More informationClinical issues which drug for which patient
Anticoagulants - a matter of heart! Towards a bright future? Clinical issues which drug for which patient Sabine Eichinger Dept. of Medicine I Medical University of Vienna/Austria Conflicts of interest
More informationDirect Oral Anticoagulants
Direct Oral Anticoagulants Holly Jahn, PharmD, CACP Objectives Identify the FDA approved indications for use, appropriate dosing, and monitoring parameters for each direct oral anticoagulant. Distinguish
More informationNOACS/DOACS*: COMPARISON AND FREQUENTLY-ASKED QUESTIONS
NOACS/DOACS*: COMPARISON AND FREQUENTLY-ASKED QUESTIONS OBJECTIVES: To provide a comparison of the newer direct oral anticoagulants (DOACs) currently available in Canada. To address frequently-asked questions
More informationNew Antithrombotic Agents
New Antithrombotic Agents Tom DeLoughery, MD FACP FAWM Oregon Health and Sciences University DISCLOSURE Relevant Financial Relationship(s) Speaker Bureau None What I am Talking About 1. New Antithrombotic
More informationNew Oral Anticoagulants in treatment of VTE, PE DR.AMR HANAFY (LECTURER OF CARDIOLOGY ) ASWAN UNIVERSITY
New Oral Anticoagulants in treatment of VTE, PE DR.AMR HANAFY (LECTURER OF CARDIOLOGY ) ASWAN UNIVERSITY Fact VTE is deadly! It nibbles after it bites! The 30-day mortality rates for first-time DVT or
More informationSouthern Trust Anticoagulant Team
CLINICAL GUIDELINES ID TAG Title: Author: Speciality / Division: Directorate: Anticoagulation- Primary Care Guidance for reviewing patients on DOACs Southern Trust Anticoagulant Team Haematology Acute
More information3/19/2012. What is the indication for anticoagulation? Has the patient previously been on warfarin? If so, what % of the time was the INR therapeutic?
Abigail E. Miller, PharmD, BCPS Clinical Specialist, Cardiology University of North Carolina Hospitals I have no personal financial relationships with the manufacturers of the products to disclose. Boehringer
More informationAre the days of Warfarin numbered?
2 nd SAVTE Symposium Are the days of Warfarin numbered? YES Dr. Mohamed A. Abdelaal, MD, FRCPath, FRCPI Consultant Haematologist King Abdulaziz Medical City - Jeddah, Saudi Arabia 1 3 May 2012, Casablanca,
More informationDOAC for VTE. Direct Oral Anticoagulants Clint Shedd DNP, FNP-BC Emory University
DOAC for VTE Direct Oral Anticoagulants Clint Shedd DNP, FNP-BC Emory University No disclosures Direct Oral Anticoagulants Understand VTE and the ACCP s position on it List the DOACs available in the US
More informationOutpatient Treatment of Deep Vein Thrombosis with Low Molecular Weight Heparin (LMWH) Clinical Practice Guideline August 2015
Outpatient Treatment of Deep Vein Thrombosis with Low Molecular Weight Heparin (LMWH) Clinical Practice Guideline August 2015 General Principles: There is compelling data in the medical literature to support
More informationDirect Oral Anticoagulants An Update
Oct. 26, 2017 Direct Oral Anticoagulants An Update Kathleen Heintz, DO, FACC Assistant Professor of Medicine Cooper Heart Institute Direct Oral Anticoagulants: DISCLAIMERS No Conflicts of Interest So what
More informationDavid Stewart, PharmD, BCPS Assistant Professor of Pharmacy Practice East Tennessee State University Bill Gatton College of Pharmacy
David Stewart, PharmD, BCPS Assistant Professor of Pharmacy Practice East Tennessee State University Bill Gatton College of Pharmacy stewardw@etsu.edu At the conclusion of this program, the audience should
More informationAfib, Stroke, and DOAC. Albert Luo, MD. Cardiology Lindsey Frischmann, DO. Neurology Xiao Cai, MD. HBS
Afib, Stroke, and DOAC Albert Luo, MD. Cardiology Lindsey Frischmann, DO. Neurology Xiao Cai, MD. HBS Disclosure of Relevant Financial Relationships I have no relevant financial relationships with commercial
More informationPractical Considerations for Using Oral Anticoagulants in Patients with Chronic Kidney Disease
Practical Considerations for Using Oral Anticoagulants in Patients with Chronic Kidney Disease Cyrille K. Cornelio, Pharm.D. PGY2 Cardiology Pharmacy Resident The University of Oklahoma College of Pharmacy
More informationOral Anticoagulation Drug Class Prior Authorization Protocol
Oral Anticoagulation Drug Class Prior Authorization Protocol Line of Business: Medicaid P & T Approval Date: February 21, 2018 Effective Date: April 1, 2018 This policy has been developed through review
More informationAnticoagulation Therapy in LTC
Anticoagulation Therapy in LTC By: Cynthia Leung, RPh, BScPhm, PharmD. Clinical Consultant Pharmacist MediSystem Pharmacy Jun 11, 2013 Agenda Stroke and Bleeding Risk Assessment Review of Oral Anticoagulation
More informationAppendix IV - Prescribing Guidance for Apixaban
Appendix IV - Prescribing Guidance for Apixaban Patient Factors Dose of Apixaban If your patient has any of the following MAJOR risk factors: Hypersensitivity to the active substance or to any of the excipients
More informationDrug Class Monograph
Drug Class Monograph Class: Oral Anticoagulants Drug: Coumadin (warfarin), Eliquis (apixaban), Pradaxa (dabigatran), Savaysa (edoxaban), arelto (rivaroxaban) Formulary Medications: Eliquis (apixaban),
More informationDIRECT ORAL ANTICOAGULANTS: WHEN TO USE, WHICH TO CHOOSE AND MANAGEMENT OF BLEEDING
DIRECT ORAL ANTICOAGULANTS: WHEN TO USE, WHICH TO CHOOSE AND MANAGEMENT OF BLEEDING KATHERINE STIRLING CONSULTANT PHARMACIST ANTICOAGULATION AND THROMBOSIS DR LISHEL HORN CONSULTANT HAEMATOLOGIST HAEMOSTASIS
More informationComparison of novel oral anticoagulants (NOACs)
Comparison of novel oral anticoagulants (NOACs) For guidance for full information refer to individual SPCs available at www.medicines.org.uk Licensed indications for NOACs Prevention of stroke and systemic
More informationIndications of Anticoagulants; Which Agent to Use for Your Patient? Marc Carrier MD MSc FRCPC Thrombosis Program Ottawa Hospital Research Institute
Indications of Anticoagulants; Which Agent to Use for Your Patient? Marc Carrier MD MSc FRCPC Thrombosis Program Ottawa Hospital Research Institute Disclosures Research Support/P.I. Employee Leo Pharma
More informationPreventing Stroke in Patients with Atrial Fibrillation: USING THE EVIDENCE
Preventing Stroke in Patients with Atrial Fibrillation: USING THE EVIDENCE What Is Atrial Fibrillation? Atrial fibrillation also called AFib or AF is the most common abnormal heart rhythm, affecting an
More informationDabigatran 101: Community Pharmacists. Peter Thomson Clinical Resource Pharmacist, Medicine Program Winnipeg Regional Health Authority
Dabigatran 101: Community Pharmacists. Peter Thomson Clinical Resource Pharmacist, Medicine Program Winnipeg Regional Health Authority Objectives At the end of this session, you should be able to: Describe
More informationNanik Hatsakorzian Pharm.D/MPH
Pharm.D/MPH 2014 1 Therapeutics FDA indication & Dosing Clinical Pearls Anticoagulants Heparin Antiphospholipid antibody syndrome Cerebral thromboembolism Prosthetic heart valve Acute coronary syndrome
More informationManagement of Novel Oral Anticoagulants (NOACs) with the DAWN AC modules
Management of Novel Oral Anticoagulants (NOACs) with the DAWN AC modules Jane Vo, Pharm D. Anticoagulation Services Scripps Clinic and Scripps Green Hospital La Jolla, California Pharmacist Management
More informationDirect Oral Anticoagulants (DOACs). Dr GM Benson Director NI Haemophilia Comprehensive Care Centre and Thrombosis Unit BHSCT
Direct Oral Anticoagulants (DOACs). Dr GM Benson Director NI Haemophilia Comprehensive Care Centre and Thrombosis Unit BHSCT OAC WARFARIN Gold standard DABIGATRAN RIVAROXABAN APIXABAN EDOXABAN BETRIXABAN
More informationWMC PHARMACY ANTICOAGULATION PROTOCOL Current Revision: July 2017 GENERAL ORDER PROCESSING AND MANAGEMENT
WMC PHARMACY ANTICOAGULATION PROTOCOL Current Revision: July 2017 GENERAL ORDER PROCESSING AND MANAGEMENT - Entering orders for anticoagulation in Cerner Providers will enter individual orders (oneoffs)
More informationThe INR: No Need Anymore? Daniel Blanchard, MD Professor of Medicine Director, Cardiology Fellowship Program UCSD Sulpizio Cardiovascular Center
The INR: No Need Anymore? Daniel Blanchard, MD Professor of Medicine Director, Cardiology Fellowship Program UCSD Sulpizio Cardiovascular Center What is the INR? Tissue Factor (Factor III) is added to
More informationNOACs in AF. Dr Colin Edwards Auckland Heart Group and Waitemata DHB. Dr Fiona Stewart Auckland Heart Group and Auckland DHB
NOACs in AF Dr Colin Edwards Auckland Heart Group and Waitemata DHB Dr Fiona Stewart Auckland Heart Group and Auckland DHB Conflict of Interest Dr Fiona Stewart received funding from Pfizer to attend the
More informationReviews. Practical Considerations for Using Novel Oral Anticoagulants in Patients With Atrial Fibrillation
Reviews Practical Considerations for Using Novel Oral Anticoagulants in Patients With Atrial Fibrillation Address for correspondence: A. John Camm, MD Division of Clinical Sciences St. George s University
More informationDrug Use Criteria: Direct Oral Anticoagulants
Texas Vendor Drug Program Drug Use Criteria: Oral Anticoagulants Publication History 1. Developed March 2017. 2. Revised February 2018. Notes: Information on indications for use or diagnosis is assumed
More informationAn Overview of Non Vitamin-K Antagonist Oral Anticoagulants. Helen Williams Consultant Pharmacist for CV Disease South London
An Overview of Non Vitamin-K Antagonist Oral Anticoagulants Helen Williams Consultant Pharmacist for CV Disease South London Contents Drugs and drug classes Licensed indications and NICE recommendations
More informationThe Use of New Anticoagulants in the Elderly NOACs, DOACs,TOACs,TSOACs.
The Use of New Anticoagulants in the Elderly NOACs, DOACs,TOACs,TSOACs. Chris E. Holmes MD, PhD Assistant Director, Thrombosis and Hemostasis Program University of Vermont Dabigatran (Praxxada) Rivoraxaban
More informationUpdates in Management of Venous Thromboembolic Disease
Updates in Management of Venous Thromboembolic Disease November 7 th 2018 UHN Emergency Conference Susan Jenkins RN(EC) NP-Adult Thrombosis and Hemostasis Program University Health Network Disclosures
More informationProfessional Practice Minutes December 7, 2016
Professional Practice Minutes December 7, 2016 **New Opportunity for Patient Education** We can now request the educational videos we want our patients to watch after our visit. Video topics include colon
More informationLet s Gi e The So ethi g To Clot About: Controversies in Anticoagulation
Let s Gi e The So ethi g To Clot About: Controversies in Anticoagulation Janna Beavers, MS, PharmD, BCPS Cardiology Clinical Pharmacy Specialist WakeMed Health & Hospitals Raleigh, NC March 13, 2018 Pharmacist
More informationAnticoagulation Beyond Coumadin
Anticoagulation Beyond Coumadin Saturday, September 21, 2013 Crystal Mountain Resort and Spa Pratik Bhattacharya MD, MPH Stroke Neurologist, Michigan Stroke Network; Assistant Professor of Neurology; Wayne
More informationNew Oral Anticoagulants
New Oral Anticoagulants Tracy Minichiello, MD Associate Professor of Medicine Chief, San FranciscoVA Anticoagulation and Thrombosis Services What percentage of time do patients on warfarin spend in therapeutic
More informationESC Congress 2012, Munich
ESC Congress 2012, Munich Anticoagulation in Atrial Fibrillation 2012: Which Anticoagulant for Which Patient? Stefan H. Hohnloser J.W. Goethe University Frankfurt am Main S.H.H. has served as a consultant,
More informationClinical Guideline for Anticoagulation in VTE
Clinical Guideline for Anticoagulation in VTE These clinical guidelines are intended to provide evidence-based recommendations regarding the anticoagulation in patients with DVT and PE. Please note that
More informationThey re Not So New Anymore Update on NOAC s (Novel Oral Anticoagulants)
They re Not So New Anymore Update on NOAC s (Novel Oral Anticoagulants) Daniel B. DiCola, MD Paul W. Ament, PharmD Daniel DiCola, MD ddicola@excelahealth.org Faculty: Latrobe Area Hospital, Excela Health
More informationUpdates in Anticoagulation for Atrial Fibrillation and Venous Thromboembolism
Disclosures Updates in Anticoagulation for Atrial Fibrillation and Venous Thromboembolism No financial conflicts of interest Member of the ABIM Focused- Practice in Hospital Medicine Self Examination Process
More informationThe Role of Oral Anticoagulants in Atrial Fibrillation: What You Need to Know Now. Bradley A. Hardin, MD Richard F.
The Role of Oral Anticoagulants in Atrial Fibrillation: What You Need to Know Now Bradley A. Hardin, MD Richard F. Otten, MD, FACC Outline Atrial Fibrillation Overview Overview of New Oral Anticoagulants
More informationUpdates in Coagulation Thrombophilia testing and direct oral anticoagulants. Kevin Y. Chen, MD Hematology and Medical Oncology October 13, 2017
Updates in Coagulation Thrombophilia testing and direct oral anticoagulants Kevin Y. Chen, MD Hematology and Medical Oncology October 13, 2017 No conflicts of interest Introduction to thrombosis Hemostasis
More informationAnticoagulation: Novel Agents
Anticoagulation: Novel Agents Scott C. Woller, MD Medical Director, Anticoagulation Management, Intermountain Healthcare Central Region, co-director Venous Thromboembolism Program, Intermountain Medical
More informationPRESENTATION TITLE. Case Studies
PRESENTATION TITLE Case Studies 1) SH is a 67 year old male. He has a history of type 2 diabetes, controlled hypertension and peripheral artery disease. He takes naproxen 500mg bd for arthritis and admits
More informationFACTOR Xa AND PAR-1 BLOCKER : ATLAS-2, APPRAISE-2 & TRACER TRIALS
New Horizons In Atherothrombosis Treatment 2012 순환기춘계학술대회 FACTOR Xa AND PAR-1 BLOCKER : ATLAS-2, APPRAISE-2 & TRACER TRIALS Division of Cardiology, Jeonbuk National University Medical School Jei Keon Chae,
More informationDIRECT ORAL ANTICOAGULANTS
2017 Cardiovascular Symposium DIRECT ORAL ANTICOAGULANTS ERNESTO UMAÑA, MD, FACC ORAL ANTICOAGULANTS Vitamin K Antagonists (VKAs): Warfarin Non Vitamin K Antagonists Direct oral anticoagulants Novel Oral
More informationADC Slides for Presentation 02/10/2017
ADC 2017 Slides for Presentation ANTI THROMBOTIC THERAPY FOR NON VALVULAR ATRIAL FIBRILLATION IN PATIENTS WITH CHRONIC KIDNEY DISEASE: CURRENT VIEWS Martin A. Alpert, MD Brent M. Parker Professor of Medicine
More informationXarelto (rivaroxaban) Prescriber Guide
Xarelto (rivaroxaban) Prescriber Guide October 2018 PP-XAR-IE-0031 Contents Patient Alert Card 4 Dosing Recommendations 4 Stroke prevention in adult patients with non-valvular atrial fibrillation 4 Patients
More informationADVANCES IN ANTICOAGULATION
ADVANCES IN ANTICOAGULATION The Clinicians Perspective Claudine M. Lewis Cardiologist OUTLINE Indications for anticoagulants Review - Physiology of Hemostasis Types of anticoagulants New anticoagulants
More informationMEDICAL ASSISTANCE HANDBOOK PRIOR AUTHORIZATION OF PHARMACEUTICAL SERVICES. A. Prescriptions That Require Prior Authorization
MEDICAL ASSISTANCE HBOOK PRI AUTHIZATION OF PHARMACEUTICAL SERVICES I. Requirements for Prior Authorization of Anticoagulants A. Prescriptions That Require Prior Authorization Prescriptions for Anticoagulants
More informationOverview of anticoagulants David Perry
Chapter 2 Overview of anticoagulants David Perry Historically anticoagulation involved the use of heparin and its derivatives or warfarin. However, the past few years have seen the introduction of a number
More informationAsif Serajian DO FACC FSCAI
Anticoagulation and Antiplatelet update: A case based approach Asif Serajian DO FACC FSCAI No disclosures relevant to this talk Objectives 1. Discuss the indication for antiplatelet therapy for cardiac
More informationUtilizing Anticoagulants for Atrial Fibrillation Related Stroke Prevention
Utilizing Anticoagulants for Atrial Fibrillation Related Stroke Prevention Rajat Deo, MD, MTR Assistant Professor of Medicine Division of Cardiology, Electrophysiology Section University of Pennsylvania
More informationUpdate with the New Oral Anticoagulants: Today s Issues for the Front Line Pharmacist
Update with the New Oral Anticoagulants: Today s Issues for the Front Line Pharmacist Peter Thomson, Pharm D. Clinical Resource Pharmacist, Medicine Program Winnipeg Regional Health Authority Clinical
More informationA Review of Direct-Acting Oral Anticoagulants (DOACs) and Their Use in Special Populations
A Review of Direct-Acting Oral Anticoagulants (DOACs) and Their Use in Special Populations Allison Bernard, PharmD PGY2 Ambulatory Care Resident University of Iowa Hospitals and Clinics October 25 th,
More informationDisclosures. Overview. Have you ever. The Perioperative Management of Anticoagulants. No financial conflicts of interest to disclose
Disclosures No financial conflicts of interest to disclose The Perioperative Management of Anticoagulants Margaret C. Fang, MD, MPH Associate Professor of Medicine UCSF Division of Hospital Medicine Medical
More informationAtrial Fibrillation: Risk Stratification and Treatment New Cardiovascular Horizons St. Louis September 19, 2015
Atrial Fibrillation: Risk Stratification and Treatment New Cardiovascular Horizons St. Louis September 19, 2015 Christopher E. Bauer, MD, FACC, FHRS SSM Health Heart & Vascular Care Clinical Cardiac Electrophysiology
More informationThe Age of the Novel Anticoagulants. Peter Netzler, MD April 21, 2017 Carolina Cardiology Electrophysiology
The Age of the Novel Anticoagulants Peter Netzler, MD April 21, 2017 Carolina Cardiology Electrophysiology Disclosures Speaker bureau for the Bristol-Myers Squibb and Pfizer alliance for Eliquis Direct
More informationAnticoagulation in 2014: Using the New Agents Safely
Anticoagulation in 2014: Using the New Agents Safely Tracy Minichiello, M.D. Professor of Medicine University of California, San Francisco Chief, SF VA Anticoagulation & Thrombosis Service Disclosures
More informationNew Age Anticoagulants: Bleeding Considerations
Ontario Regional Blood Coordinating Network March 23, 2012 New Age Anticoagulants: Bleeding Considerations Bill Geerts, MD, FRCPC Thromboembolism Specialist, Sunnybrook HSC Professor of Medicine, University
More informationStroke Prevention and Contemporary Management of Non-Valvular Atrial Fibrillation
Stroke Prevention and Contemporary Management of Non-Valvular Atrial Fibrillation Craig T. January, MD, PhD, FACC Division of Cardiovascular Medicine University of Wisconsin Illinois & Wisconsin Chapters
More informationNovel Anticoagulants PHYSICIANS UPDATE 2014
Novel Anticoagulants PHYSICIANS UPDATE 2014 Farouk Mookadam MD FRCPC FACC MSc Professor College of Medicine Mayo Consultant Cardiovascular Diseases Medical Director Anticoagulation Clinic Assoc Programme
More informationManaging Perioperative Anticoagulation. Edie Shen MD
Managing Perioperative Anticoagulation Edie Shen MD Anticoagulation VKA Warfarin (Coumadin) DOACs Direct Thrombin Inhibitor Dabigatran (Pradaxa) Factor Xa Inhibitor Rivaroxaban(Xarelto) Apixaban(Eliquis)
More informationChallenging Anticoagulation Case Studies. Earl J. Hope, M.D. Tower Health Cardiology
Challenging Anticoagulation Case Studies Earl J. Hope, M.D. Tower Health Cardiology Financial Disclosures Nothing to disclose Objectives: 1. Understand indications for heparin bridging. 2. Recognize the
More informationRETROSPECTIVE CLAIMS DATABASE STUDIES OF DIRECT ORAL ANTICOAGULANTS (DOACS) FOR STROKE PREVENTION IN NONVALVULAR ATRIAL FIBRILLATION
RETROSPECTIVE CLAIMS DATABASE STUDIES OF DIRECT ORAL ANTICOAGULANTS (DOACS) FOR STROKE PREVENTION IN NONVALVULAR ATRIAL FIBRILLATION Craig I. Coleman, PharmD Professor, University of Connecticut School
More informationDebate: New Generation Anti-Coagulation Agents are a Better Choice than Warfarin in the Management of AF
Debate: New Generation Anti-Coagulation Agents are a Better Choice than Warfarin in the Management of AF Bradley P. Knight, MD Director of Cardiac Electrophysiology Bluhm Cardiovascular Institute Northwestern
More informationUpdates in Stroke Management. Jessica A Starr, PharmD, FCCP, BCPS Associate Clinical Professor Auburn University Harrison School of Pharmacy
Updates in Stroke Management Jessica A Starr, PharmD, FCCP, BCPS Associate Clinical Professor Auburn University Harrison School of Pharmacy Disclosure I have no actual or potential conflict of interest
More informationKCS Congress: Impact through collaboration
Stroke Prevention in Atrial Fibrillation (SPAF) in Kenya Elijah N. Ogola FACC University of Nairobi Kenya Cardiac Society Annual Scientific Congress Mombasa 28 th June 1 st July 2017 KCS Congress: Impact
More information6 th ACC-SHA Joint Meeting Jeddah, Saudi Arabia
6 th ACC-SHA Joint Meeting Jeddah, Saudi Arabia October 31 st - November 1 st, 2015 NOACS vs. Coumadin in Atrial Fibrillation: Is It Worth to Switch? Raed Sweidan, MD, FACC Consultant and Head of Cardiac
More informationNeuroPI Case Study: Anticoagulant Therapy
Case: An 82-year-old man presents to the hospital following a transient episode of left visual field changes. His symptoms lasted 20 minutes and resolved spontaneously. He has a normal neurological examination
More informationNew and old anticoagulants. Anticoagulation Focus on Direct Oral Anticoagulants
Anticoagulation Focus on Direct Oral Anticoagulants Tzu-Fei Wang, MD Assistant Professor Department of Internal Medicine Division of Hematology The Ohio State University Wexner Medical Center Objectives
More informationAtrial fibrillation and anticoagulation JIR-PING BOEY, DEPARTMENT OF HAEMATOLOGY, FLINDERS MEDICAL CENTRE FEBRUARY 2016
1 Atrial fibrillation and anticoagulation JIR-PING BOEY, DEPARTMENT OF HAEMATOLOGY, FLINDERS MEDICAL CENTRE FEBRUARY 2016 Disclosures 2 No conflicts of interest Some questions 3 Should my patient with
More informationApixaban for Atrial Fibrillation in Patients with End-Stage Renal Disease on Dialysis
Apixaban for Atrial Fibrillation in Patients with End-Stage Renal Disease on Dialysis Caitlin Reedholm, PharmD PGY1 Pharmacy Resident St. David s South Austin Medical Center November 2, 2018 Abbreviations
More informationNEW ZEALAND DATASHEET
1. PRODUCT NAME PRADAXA 75 mg hard capsules PRADAXA 110 mg hard capsules PRADAXA 150 mg hard capsules NEW ZEALAND DATASHEET 2. QUALITATIVE AND QUANTITATIVE COMPOSITION PRADAXA 75 mg hard capsules Each
More informationNUOVI ANTICOAGULANTI NELL ANZIANO: indicazioni e controindicazioni. Mario Cavazza Medicina d Urgenza Pronto Soccorso AOU di Bologna
NUOVI ANTICOAGULANTI NELL ANZIANO: indicazioni e controindicazioni Mario Cavazza Medicina d Urgenza Pronto Soccorso AOU di Bologna Two major concerns Atrial Fibrillation: Epidemiology The No. 1 preventable
More informationCost and Prevalence of A fib. Atrial Fibrillation: Guideline Directed Treatment. Prevalence of A Fib. Risk Factors for A Fib. Risk Factors for A Fib
Atrial Fibrillation: Guideline Directed Treatment Melissa Wendell, FNP-C, MSN Heart Failure - Lead Nurse Practitioner, Aspirus Wausau Hospital and Aspirus Cardiology Cost and Prevalence of A fib 33.5 million
More informationDo s and Don t of DOACs DISCLOSURE
Do s and Don t of DOACs Tom DeLoughery, MD MACP FAWM Oregon Health and Sciences University DISCLOSURE Relevant Financial Relationship(s) Speaker Bureau - None Consultant/Research none Content Expert: Elsevier
More informationMEDICAL ASSISTANCE BULLETIN
ISSUE DATE July 5, 2016 SUBJECT EFFECTIVE DATE July 11, 2016 MEDICAL ASSISTANCE BULLETIN NUMBER *See below BY Prior Authorization of Anticoagulants - Pharmacy Services Leesa M. Allen, Deputy Secretary
More informationAnticoagulation with Direct oral anticoagulants (DOACs) and advances in peri-procedural interruption of anticoagulation-- Bridging
Anticoagulation with Direct oral anticoagulants (DOACs) and advances in peri-procedural interruption of anticoagulation-- Bridging Scott C. Woller, MD Co-Director, Thrombosis Program Intermountain Medical
More informationINR as a Biomarker: Anticoagulation in Atrial Fib, Heart Failure, and Cardiovascular Disease Daniel Blanchard, MD, FACC, FAHA
INR as a Biomarker: Anticoagulation in Atrial Fib, Heart Failure, and Cardiovascular Disease Daniel Blanchard, MD, FACC, FAHA Professor of Medicine Director, Cardiology Fellowship Program Sulpizio Cardiovascular
More informationWarfarin for Long-Term Anticoagulation. Disadvantages of Warfarin. Narrow Therapeutic Window. Warfarin vs. NOACs. Challenges Monitoring Warfarin
1 2:15 pm The Era of : Selecting the Best Approach to Treatment SPEAKER Gregory Piazza, MD, MS Presenter Disclosure Information The following relationships exist related to this presentation: Gregory Piazza,
More informationTransitions of care in anticoagulated patients
Journal of Multidisciplinary Healthcare open access to scientific and medical research Open Access Full Text Article Transitions of care in anticoagulated patients Expert Opinion Franklin Michota Department
More information04/13/2015. Disclosures Target Specific Oral Anticoagulants (TSOACS) and Areas for Pharmacy Involvement. Abbreviations. Learning Objectives TSOACS
1 2 Disclosures Target Specific Oral Anticoagulants (TSOACS) and Areas for Pharmacy Involvement I have nothing to disclose concerning possible financial or personal relationships with commercial entities
More informationMODULE 1: Stroke Prevention in Atrial Fibrillation Benjamin Bell, MD, FRCPC
MODULE 1: Stroke Prevention in Atrial Fibrillation Benjamin Bell, MD, FRCPC Specialty: General Internal Medicine Lecturer, Department of Medicine University of Toronto Staff Physician, General Internal
More informationWhen and how to combine antiplatelet agents and anticoagulant?
When and how to combine antiplatelet agents and anticoagulant? Christophe Beauloye, MD, PhD Head, Division of Cardiology Cliniques Universitaires Saint-Luc Brussels, Belgium Introduction Anticoagulation
More informationANTICOAGULATION: THE DO'S AND DON'TS OF BRIDGE THERAPY
ANTICOAGULATION: THE DO'S AND DON'TS OF BRIDGE THERAPY SATURDAY/11:30AM-12:30PM ACPE UAN: 0107-9999-17-236-L01-P 0.1 CEU/1.0 hr Activity Type: Application-Based Learning Objectives for Pharmacists: Upon
More information